Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ranmark

- PMLiVE

Will Shire agree to extend Takeda takeover talks?

UK rules mean Shire must agree to extend deadline

- PMLiVE

Shire rebuffs Takeda bids, as Allergan bows out

Allergan doesn’t intend to make a formal offer following a dip in its share prices

- PMLiVE

GSK hands rare disease assets over to Orchard

The UK pharma group will take a 19.9% stake in its ex-rival

- PMLiVE

Takeda mulls bid for Irish biopharma Shire

The Japanese pharma firm must make a formal offer by 25 April

- PMLiVE

GSK buys Novartis out of consumer health JV after ditching Pfizer bid

Will pay $13bn for the 36.5% stake owned by the Swiss drug maker

- PMLiVE

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease

- PMLiVE

GSK joins Reckitt in passing on Pfizer’s consumer health unit

The healthcare business doesn’t meet GSK’s criteria for returns, says Walmsley

- PMLiVE

EMA starts review of Xtandi in non-metastatic prostate cancer

The evaluation is based on positive results from the PROSPER trial

- PMLiVE

Ex-GSK CEO Witty named head of pharmacy benefit firm Optum

Current Optum CEO Larry Renfro will move to Optum Ventures as MD

Otsuka rewards digital health startup NeuroFlow

Mental illness tech platform wins the pharma firm's US pitch challenge

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links